Vicarious Surgical Inc.

Vicarious Surgical Inc. Annual Report Summary (Fiscal Year Ended December 31, 2025)

Vicarious Surgical Inc. aims to revolutionize minimally invasive surgery with its innovative robotic system. This summary provides a concise overview of the company's performance and outlook, based on its latest annual report for the fiscal year ended December 31, 2025. It incorporates key financial insights and significant events, including those occurring after the fiscal year-end.

1. Business Overview

Vicarious Surgical develops the Vicarious Surgical System, an innovative single-port surgical robot. This medical technology company seeks to transform minimally invasive surgery by combining miniaturized robotics, advanced computer science, and 3D visualization. Its design gives surgeons "human-like motion" with nine degrees of freedom through a single, small incision, promising enhanced precision, improved surgeon ergonomics, and greater efficiency. Ultimately, the company aims to improve patient outcomes and reduce healthcare costs. The system has demonstrated capabilities in early studies, including cadaveric trials, and initially targets procedures like ventral hernia repair.

2. Financial Performance

As a development-stage company, Vicarious Surgical has not yet generated revenue from product sales.

• Revenue: $0 from product sales for the fiscal year ended December 31, 2025.
• Net Loss: The company reported a significant net loss for the fiscal year ended December 31, 2025. This continues a trend of substantial losses since the company's inception. Management anticipates significant losses for the foreseeable future as development and commercialization efforts continue.
• Year-over-Year Changes: Given the company's development stage and lack of product sales revenue, year-over-year revenue growth is not applicable.

3. Risk Factors

Investors in Vicarious Surgical face several significant and immediate risks:

• Liquidity Crisis: The most immediate and severe risk is the company's urgent need for additional funding. Failure to secure this capital would jeopardize its ability to continue operations and could lead to bankruptcy.
• Regulatory Hurdles: Uncertainty and potential delays in obtaining FDA approval for the Vicarious Surgical System are paramount. Without approval, the company cannot sell its product.
• Market Acceptance & Competition: Even with regulatory approval, widespread adoption is not guaranteed in a highly competitive market dominated by established players like Intuitive Surgical, Medtronic, and Johnson & Johnson.
• Delisting & Liquidity: Trading on the OTC Pink Market significantly reduces liquidity, investor interest, and institutional investment. This could lead to greater price volatility and difficulty selling shares.
• Financial Reporting Reliability: The identified material weakness in internal controls poses a risk of inaccurate financial statements, which could undermine investor trust.
• Intellectual Property: Risks include protecting its proprietary technology and potential infringement claims from competitors.
• Key Personnel Reliance: The business relies heavily on its specialized technical and management team. Losing key individuals could severely impact operations.

4. Management's Discussion and Analysis (MD&A) Highlights

Management's discussion highlights the company's operational progress and significant financial challenges during and after the fiscal year ended December 31, 2025.

• Results of Operations: The company continued operating as a development-stage entity, incurring substantial research and development expenses to advance the Vicarious Surgical System. This led to a significant net loss for FY2025, consistent with prior periods and expected as the company progresses towards commercialization without product sales revenue.
• Liquidity and Capital Resources: The company's liquidity is severely constrained by its high cash burn rate and lack of revenue. Management explicitly acknowledges substantial doubt about the company's ability to continue operating without securing significant additional capital. The recent NYSE delisting and transition to OTC trading are expected to further complicate capital raising efforts and reduce the liquidity of its common stock.
• Key Developments & Challenges:
  • NYSE Delisting: On March 3, 2026, the NYSE delisted the company's common stock and suspended trading. It subsequently moved to the OTC Pink Market. This event significantly impacts the company's public profile, investor access, and potential for future capital raises.
  • Reverse Stock Split: The company executed a 1-for-30 reverse stock split in June 2024. This was an attempt to maintain listing compliance, but it ultimately did not prevent delisting.
  • Regulatory Status: The Vicarious Surgical System has not yet received marketing authorization from the U.S. FDA. The regulatory approval process is complex, lengthy, and uncertain, representing a critical hurdle to commercialization.
  • Internal Controls: The company identified a material weakness in its internal control over financial reporting. This indicates a significant deficiency that could lead to material misstatements in financial reporting, raising concerns about the reliability of financial information.
  • Development Progress: Despite financial hurdles, the company continues to advance its surgical system's development through ongoing testing and refinement.

5. Financial Health

The company's financial health reflects its early development stage, significant cash burn, and reliance on external funding.

• Liquidity: The company has a high cash burn rate. This high burn rate, coupled with a lack of revenue, poses a significant liquidity challenge.
• Going Concern: Management has explicitly stated substantial doubt about the company's ability to continue operating without securing significant additional funding in the near future. This critical disclosure indicates potential insolvency if new capital is not raised.
• Market Capitalization: As of June 30, 2025, the company's market capitalization was approximately $38.8 million.

6. Future Outlook

Vicarious Surgical's core strategy centers on developing and commercializing its surgical system.

• Commercialization Goal: The primary objective is to obtain FDA marketing authorization to begin commercial sales in the U.S., followed by potential international expansion.
• Funding Imperative: All future plans, including continued development and commercialization, critically depend on the company's ability to successfully raise substantial additional capital. Without this funding, development efforts could face significant delays, scaling back, or even termination, potentially leading to the cessation of operations.
• Leadership: A team with strong technical backgrounds, including engineers from MIT, leads the company, driving its innovative approach.

7. Competitive Position

Vicarious Surgical operates in the highly competitive and rapidly evolving market for robot-assisted minimally invasive surgery.

• Key Competitors: Established players with significant resources dominate the market, including Intuitive Surgical, Medtronic, and Johnson & Johnson. These competitors possess extensive commercialization infrastructure, regulatory experience, and intellectual property portfolios, presenting substantial barriers to entry and market penetration.
• Competitive Advantages (Aspirations): The company aims to differentiate its Vicarious Surgical System through its unique single-port design, "human-like motion," and enhanced precision. It believes these features offer advantages in surgeon ergonomics, efficiency, and patient outcomes compared to existing multi-port robotic systems.
• Challenges: Despite its innovative approach, the company faces significant challenges. It must gain market acceptance against entrenched competitors and requires substantial capital to achieve commercialization and build out its sales and support infrastructure. The highly regulated medical device industry makes FDA authorization paramount for market entry and commercial success.

Conclusion

Vicarious Surgical Inc. presents an innovative technological vision in surgical robotics. However, it currently navigates severe financial and operational challenges, most notably an urgent need for funding and its recent NYSE delisting. These factors introduce substantial risk for investors, making the company's future highly uncertain without significant capital infusion and successful regulatory approval.